Sales of Abbott's coronary stents - which are used to prop open damaged arteries - rose 124.5% to $410 million.

(In =UPDATE: Abbott 4Q Net Up 28% On Xience, Humira Sales Growth," published at 11:13 a.m. EST, the sales figure was incorrect)

Click here to go to Dow Jones NewsPlus, a web front page of today's most important business and market news, analysis and commentary. You can use this link on the day this article is published and the following day.